PRTA News and Press, Prothena Corporation plc From 09/14/22

Summary Electrovaya, an early dotcom child, managed to outlive its vigorous competition and develop one of today's leading battery technologies. Over the previous years, the company’s scale-up efforts failed. History could repeat itself as the management lacks manufacturing...

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team...

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Helen S. Kim, MBA, to i...

Prothena press release ( NASDAQ: PRTA ): Q2 GAAP EPS of -$0.88 misses by $0.31 . Collaboration revenue of $1.31M. As of June 30, 2022, Prothena had $510.1 million in cash, cash equivalents and restricted cash, and no debt. Outlook: The company continue...

Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1 million Broad Alzheimer’s disease portfolio continues to ad...

Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...

DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter...

The electric vehicle sector is having a strong day to cut into the anxiety that has built up over supply chain problems, inflation costs and the impact of higher interest rates on valuation. Leading the EV pack, Workhorse Group ( NASDAQ: WKHS ) shot up 15.85% after a big...

A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease did not meet key goals in a mid-stage trial. Developed by the fellow Swiss biote...

DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management ...